A Randomized, Open-label, Three-period, Three-sequence, Multiple Dosing Crossover, Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 After Co-administration of DWP14012 and DWC202201 in Healthy Subjects
Latest Information Update: 17 Apr 2023
At a glance
- Drugs Fexuprazan (Primary) ; Atorvastatin
- Indications Bleeding ulcer; Erosive oesophagitis; Gastritis; Gastro-oesophageal reflux; Peptic ulcer; Reflux oesophagitis
- Focus Pharmacokinetics
- Sponsors Daewoong Pharmaceutical
Most Recent Events
- 17 Apr 2023 New trial record